Comprehensive Stock Comparison
Compare FibroGen, Inc. (FGEN) vs Kymera Therapeutics, Inc. (KYMR) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | KYMR | -16.7% revenue growth vs FGEN's -36.7% |
| Quality / Margins | FGEN | -160.6% net margin vs KYMR's -7.9% |
| Stability / Safety | FGEN | Beta 1.21 vs KYMR's 1.31 |
| Dividends | FGEN | 0.3% yield; 1-year raise streak; KYMR pays no meaningful dividend |
| Momentum (1Y) | KYMR | +191.4% vs FGEN's -26.5% |
| Efficiency (ROA) | FGEN | 157.4% ROA vs KYMR's -17.9% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
FibroGen is a biopharmaceutical company focused on developing novel therapeutics for serious medical conditions like anemia and fibrotic diseases. It generates revenue primarily through collaboration agreements with major pharmaceutical partners — including Astellas and AstraZeneca — which provide upfront payments, milestone payments, and royalties on future sales. The company's competitive advantage lies in its expertise in hypoxia-inducible factor biology and connective tissue growth factor inhibition, which has produced two late-stage drug candidates with novel mechanisms of action.
Kymera Therapeutics is a biopharmaceutical company developing targeted protein degraders — small molecules that harness the body's natural protein degradation system to eliminate disease-causing proteins. It generates revenue primarily through strategic partnerships and milestone payments from pharmaceutical collaborators — with potential future revenue from drug sales if clinical candidates succeed. The company's key advantage is its proprietary Pegasus platform for discovering novel protein degraders, which targets previously "undruggable" proteins and creates a pipeline of first-in-class therapies.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
KYMR leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). FGEN leads in 1 (Financial Metrics). 2 tied.
Financial Metrics (TTM)
KYMR and FGEN operate at a comparable scale, with $39M and -$118M in trailing revenue. Profitability is closely matched — net margins range from -160.6% (FGEN) to -7.9% (KYMR). On growth, KYMR holds the edge at -61.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | FGENFibroGen, Inc. | KYMRKymera Therapeuti… |
|---|---|---|
| RevenueTrailing 12 months | -$118M | $39M |
| EBITDAEarnings before interest/tax | -$123M | -$349M |
| Net IncomeAfter-tax profit | $216M | -$311M |
| Free Cash FlowCash after capex | -$17M | -$234M |
| Gross MarginGross profit ÷ Revenue | +47.5% | +100.0% |
| Operating MarginEBIT ÷ Revenue | -5.1% | -8.9% |
| Net MarginNet income ÷ Revenue | -160.6% | -7.9% |
| FCF MarginFCF ÷ Revenue | -4.7% | -6.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | -97.7% | -61.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +12.7% | -11.4% |
Valuation Metrics
| Metric | FGENFibroGen, Inc. | KYMRKymera Therapeuti… |
|---|---|---|
| Market CapShares × price | $585M | $7.4B |
| Enterprise ValueMkt cap + debt − cash | $625M | $7.2B |
| Trailing P/EPrice ÷ TTM EPS | -15.63x | -24.76x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 19.75x | 189.51x |
| Price / BookPrice ÷ Book value/share | — | 4.88x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
FGEN delivers a 12.3% return on equity — every $100 of shareholder capital generates $12 in annual profit, vs $-20 for KYMR. On the Piotroski fundamental quality scale (0–9), KYMR scores 4/9 vs FGEN's 2/9, reflecting mixed financial health.
| Metric | FGENFibroGen, Inc. | KYMRKymera Therapeuti… |
|---|---|---|
| ROE (TTM)Return on equity | +12.3% | -19.7% |
| ROA (TTM)Return on assets | +157.4% | -17.9% |
| ROICReturn on invested capital | — | -24.9% |
| ROCEReturn on capital employed | -104.8% | -27.2% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 4 |
| Debt / EquityFinancial leverage | — | 0.05x |
| Net DebtTotal debt minus cash | $40M | -$275M |
| Cash & Equiv.Liquid assets | $50M | $357M |
| Total DebtShort + long-term debt | $90M | $82M |
| Interest CoverageEBIT ÷ Interest expense | -20.28x | -1403.21x |
Total Returns (with DRIP)
A $10,000 investment in KYMR five years ago would be worth $18,851 today (with dividends reinvested), compared to $59 for FGEN. Over the past 12 months, KYMR leads with a +191.4% total return vs FGEN's -26.5%. The 3-year compound annual growth rate (CAGR) favors KYMR at 42.8% vs FGEN's -76.2% — a key indicator of consistent wealth creation.
| Metric | FGENFibroGen, Inc. | KYMRKymera Therapeuti… |
|---|---|---|
| YTD ReturnYear-to-date | -18.1% | +25.5% |
| 1-Year ReturnPast 12 months | -26.5% | +191.4% |
| 3-Year ReturnCumulative with dividends | -98.6% | +191.1% |
| 5-Year ReturnCumulative with dividends | -99.4% | +88.5% |
| 10-Year ReturnCumulative with dividends | -98.3% | +174.7% |
| CAGR (3Y)Annualised 3-year return | -76.2% | +42.8% |
Risk & Volatility
FGEN is the less volatile stock with a 1.21 beta — it tends to amplify market swings less than KYMR's 1.31 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KYMR currently trades 88.7% from its 52-week high vs FGEN's 59.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | FGENFibroGen, Inc. | KYMRKymera Therapeuti… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.21x | 1.31x |
| 52-Week HighHighest price in past year | $12.60 | $103.00 |
| 52-Week LowLowest price in past year | $4.85 | $19.45 |
| % of 52W HighCurrent price vs 52-week peak | +59.5% | +88.7% |
| RSI (14)Momentum oscillator 0–100 | 39.4 | 77.9 |
| Avg Volume (50D)Average daily shares traded | 27K | 620K |
Analyst Outlook
Wall Street rates FGEN as "Hold" and KYMR as "Buy". Consensus price targets imply 273.3% upside for FGEN (target: $28) vs 28.4% for KYMR (target: $117). FGEN is the only dividend payer here at 0.30% yield — a key consideration for income-focused portfolios.
| Metric | FGENFibroGen, Inc. | KYMRKymera Therapeuti… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $28.00 | $117.31 |
| # AnalystsCovering analysts | 14 | 26 |
| Dividend YieldAnnual dividend ÷ price | +0.3% | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | $0.02 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Sep 20 | Feb 26 | Change |
|---|---|---|---|
| FibroGen, Inc. (FGEN) | 100 | 0.73 | -99.3% |
| Kymera Therapeutics… (KYMR) | 93.69 | 227.36 | +142.7% |
Kymera Therapeutics… (KYMR) returned +89% over 5 years vs FibroGen, Inc. (FGEN)'s -99%. A $10,000 investment in KYMR 5 years ago would be worth $18,851 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| FibroGen, Inc. (FGEN) | $180M | $30M | -83.5% |
| Kymera Therapeutics… (KYMR) | $0.00 | $39M | — |
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| FibroGen, Inc. (FGEN) | -34.3% | -160.6% | -367.7% |
| Kymera Therapeutics… (KYMR) | -14.1% | -7.9% | +43.6% |
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| FibroGen, Inc. (FGEN) | -0.98 | -0.48 | +51.0% |
| Kymera Therapeutics… (KYMR) | -0.48 | -3.69 | -668.8% |
Chart 5Free Cash Flow — 5 Years
FibroGen, Inc. generated $-138M FCF in 2024 (-23% vs 2021). Kymera Therapeutics, Inc. generated $-234M FCF in 2025 (-80% vs 2021).
FGEN vs KYMR: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is FGEN or KYMR a better buy right now?
Analysts rate Kymera Therapeutics, Inc. (KYMR) a "Buy" — based on 26 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — FGEN or KYMR?
Over the past 5 years, Kymera Therapeutics, Inc. (KYMR) delivered a total return of +88.5%, compared to -99.4% for FibroGen, Inc. (FGEN). A $10,000 investment in KYMR five years ago would be worth approximately $19K today (assuming dividends reinvested). Over 10 years, the gap is even starker: KYMR returned +174.7% versus FGEN's -98.3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — FGEN or KYMR?
By beta (market sensitivity over 5 years), FibroGen, Inc. (FGEN) is the lower-risk stock at 1.21β versus Kymera Therapeutics, Inc.'s 1.31β — meaning KYMR is approximately 8% more volatile than FGEN relative to the S&P 500.
04Which has better profit margins — FGEN or KYMR?
FibroGen, Inc. (FGEN) is the more profitable company, earning -160.6% net margin versus -794.4% for Kymera Therapeutics, Inc. — meaning it keeps -160.6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: FGEN leads at -507.8% versus -891.3% for KYMR. At the gross margin level — before operating expenses — KYMR leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — FGEN or KYMR?
In this comparison, FGEN (0.3% yield) pays a dividend. KYMR does not pay a meaningful dividend and should not be held primarily for income.
06Is FGEN or KYMR better for a retirement portfolio?
For long-horizon retirement investors, Kymera Therapeutics, Inc. (KYMR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+174.7% 10Y return). Both have compounded well over 10 years (KYMR: +174.7%, FGEN: -98.3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between FGEN and KYMR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.